J.K.K.Nattraja College of Pharmacy, Kumarapalayam, Namakkal district, Tamilnadu, India.
Department of Pharmacy Practice, J.K.K.Nattraja College of Pharmacy, Kumarapalayam, Namakkal district, Tamilnadu, India.
Curr Cardiol Rev. 2024;20(2):50-60. doi: 10.2174/011573403X273613240125072754.
Previous publications in 2011, 2016, and 2022 have presented lists of drugs associated with takotsubo cardiomyopathy (TCM). This review aims to provide updated drug lists that have been reported as potential causes of TCM.
Following the same methodology employed in previous reviews, a detailed investigation was carried out in the PubMed/Medline database from June 2022 to July 2023 to identify drug-induced TCM (DITC) case reports. Various search terms related to the drug-induced transient left ventricular ballooning syndrome, ampulla cardiomyopathy, apical ballooning syndrome, drug-induced broken heart syndrome, drug triggered takotsubo cardiomyopathy, takotsubo cardiomyopathy, and iatrogenic takotsubo cardiomyopathy were utilized. Filters for fulltext availability, case reports, human studies, and English language were applied. Articles reporting drugs associated with TCM development were included in the analysis.
Foremost 192 case reports were initially identified, with 75 drugs meeting the inclusion criteria after a thorough review. The latest revision identified seven drugs that might lead to TCM, with four drugs (57.14%) already reported in previous reviews and three drugs (42.86%) newly identified. Consequently, the updated drug list potentially triggering TCM in 2023 comprises a sum of 75 drugs.
The recent 75 drugs provided additional evidence linking to TCM development. The updated list predominantly includes drugs that induce sympathetic overstimulation, although some drugs on the list have unclear associations with sympathetic nervous system activation.
先前在 2011 年、2016 年和 2022 年发表的出版物已经列出了与 Takotsubo 心肌病（TCM）相关的药物。本综述旨在提供已报道为潜在 TCM 病因的更新药物清单。
按照先前综述中采用的相同方法，在 2022 年 6 月至 2023 年 7 月期间，对 PubMed/Medline 数据库进行了详细调查，以确定药物诱导的 TCM（DITC）病例报告。使用了与药物诱导的短暂左心室球囊样综合征、壶腹心肌病、心尖球囊样综合征、药物性心碎综合征、药物触发的 Takotsubo 心肌病、Takotsubo 心肌病和医源性 Takotsubo 心肌病相关的各种搜索词。应用了全文可用性、病例报告、人类研究和英语语言过滤器。纳入分析的文章报告了与 TCM 发展相关的药物。
最初确定了 192 篇病例报告，经过彻底审查后，有 75 种药物符合纳入标准。最新修订版确定了可能导致 TCM 的七种药物，其中四种药物（57.14%）已在先前的综述中报道，三种药物（42.86%）是新发现的。因此，2023 年潜在触发 TCM 的更新药物清单包括 75 种药物。
最近的 75 种药物提供了更多与 TCM 发展相关的证据。更新的清单主要包括引起交感神经过度刺激的药物，尽管清单上的一些药物与交感神经系统激活的关联尚不清楚。
